BIG PHARMA WATCH: NEW ANALYSIS FINDS BIG PHARMA REAPS BIG MULTIPLES FROM MEDICARE SPENDING ON TOP DRUGS

05-13-2022 Blog Posts

Part D Spending on 10 Most Popular Medications Over Five Years Averages Five Times What Drug Companies Claim to Invest in R&D In case you missed it, AARP’s Public Policy Institute released a new analysis Wednesday examining Medicare Part D spending over a year five year period, from 2016 to 2020, on the 10 top-selling brand name […]

BIG PHARMA EARNINGS WATCH: BRISTOL-MYERS SQUIBB, ABBVIE, ASTRAZENECA AND PFIZER

05-6-2022 Blog Posts

Another Round of Big Pharma Giants Beat Wall Street Expectations In Q1 After Hiking Prices Throughout Pandemic Big Pharma giants Bristol-Myers Squibb, Pfizer, AbbVie and AstraZeneca all held earnings calls within the past week that beat Wall Street analysts’ expectations. The brand name drug companies’ strong earnings came after the companies launched several rounds of […]

DOSE OF REALITY: SENATE COMMERCE HEARING OPPORTUNITY FOR LAWMAKERS TO HOLD BIG PHARMA ACCOUNTABLE

05-3-2022 Blog Posts

Lawmakers Should Focus Attention on Brand Name Drug Companies’ Egregious Practices, Recommit to Market-Based Solutions to Lower Drug Prices On Thursday, May 5, the U.S. Senate Committee on Commerce, Science and Transportation’s Subcommittee on Consumer Protection, Product Safety, and Data Security is set to hold a hearing on “Ensuring Fairness and Transparency in the Market […]

BIG PHARMA EARNINGS WATCH: NOVARTIS, GLAXOSMITHKLINE, AMGEN, ROCHE

04-29-2022 Blog Posts

Big Pharma Giants Repeatedly Hike Prices and Continue to Beat Wall Street Expectations This week, Novartis, GlaxoSmithKline, Amgen, and Roche all reported earnings for the first quarter. All four Big Pharma giants engaged in price hikes during the COVID-19 pandemic and have a history of engaging in anti-competitive tactics to undermine competition and drive-up prices. […]

ICYMI: NEW SURVEY FINDS VOTERS CONTINUE TO BLAME BIG PHARMA FOR OUT-OF-CONTROL DRUG PRICES, SUPPORT CONGRESSIONAL ACTION

04-27-2022 Blog Posts

Patients for Affordable Drugs Now Poll Finds Vast Majority of Voters Reject Pharmaceutical Industry Rhetoric, Want Lawmakers to Hold Big Pharma Accountable A new national survey from Patients for Affordable Drugs Now shows the vast majority of American voters continue to support solutions to lower prescription drug prices by holding Big Pharma accountable. The survey […]

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

04-20-2022 Blog Posts

J&J Beats Q1 Earnings Expectations, Announces Dividend Increase After Hiking Prices on Dozens of Brand Name Drugs This week, Johnson & Johnson kicked off the first round of Big Pharma earnings reports for the first quarter of 2022. Yet again, the Big Pharma giant surpassed Wall Street analysts’ earnings expectations, growing sales and posting massive […]

ICYMI: THE NEW YORK TIMES EDITORIAL BOARD ENDORSES SOLUTIONS TO CRACK DOWN ON BIG PHARMA’S PATENT ABUSE

04-18-2022 Blog Posts

Highlights How Administration and Lawmakers Can Fix Loopholes Exploited by Pharmaceutical Companies to Keep Drug Prices High A new editorial from The New York Times Editorial Board highlights how Big Pharma games the system to keep drug prices high and calls for reforms to increase competition and help lower drug prices for the American people. […]

BIG PHARMA WATCH: BRANDED DRUG COMPANIES MORE THAN DOUBLED PRICES FOR BLOCKBUSTER BLOOD THINNING MEDICATIONS OVER TEN YEARS

04-7-2022 Blog Posts

New Report Demonstrates How Brand Name Drug Companies Work in “Lockstep” to Hit Patients with Higher Prices on Life-Saving Medications In case you missed it, a new report this week from Patients for Affordable Drugs (P4AD) looks into the history of two blockbuster blood-thinning medications, Bristol Myers Squibb and Pfizer’s Eliquis and Johnson & Johnson’s […]

DOSE OF REALITY: NEW STUDY FINDS ONE THIRD OF SENIORS DO NOT FILL PRESCRIPTIONS FOR HIGH-PRICE DRUGS USED TO TREAT SERIOUS CONDITIONS

04-6-2022 Blog Posts

Academic Study Underscores How Big Pharma’s Price-Gouging on Treatments for Diseases Like Cancer Drives Crisis of Affordability An academic analysis published this week in Health Affairs examines Medicare enrollees’ habits when prescribed new, high-price specialty drugs for four specific conditions. The analysis compares the difference between the number of prescriptions filled and picked up for […]

THEY SAID IT! FINANCE COMMITTEE HIGHLIGHTS URGENCY TO HOLD BIG PHARMA ACCOUNTABLE FOR PRICE HIKES AND ANTI-COMPETITIVE BEHAVIOR

03-17-2022 Blog Posts

Lawmakers Double-Down on Repeated Promises to the American People to Lower Prescription Drug Prices and Crack Down on Brand Name Drug Companies During a hearing Wednesday before the U.S. Senate Committee on Finance, lawmakers on both sides of the aisle emphasized the need for urgent action to lower prescription drug prices by holding Big Pharma […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.